Bellerophon Biotec Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 260.81%
- Profit Growth 44.85%
- Ebitda 41.36%
- Net Worth -7.99%
- Total Assets -11.33%
About Bellerophon Biotec
Bellerophon Biotec Private Limited (BBPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 September 2012 and has a history of 12 years and five months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Aman Chawla and Pcheena Chawla serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24100DL2012PTC242038
-
Company No.
242038
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Sep 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Bellerophon Biotec Private Limited offer?
Bellerophon Biotec Private Limited offers a wide range of products and services, including Immunization & Vaccination Drugs, Infant Vaccines, Vaccines, Common Disease Medicines, Injectable Products, Rabies Vaccine.
Who are the key members and board of directors at Bellerophon Biotec?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pcheena Chawla
|
Director | 11-Sep-2012 | Current |
|
Aman Chawla
|
Director | 05-May-2014 | Current |
Financial Performance of Bellerophon Biotec.
Bellerophon Biotec Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 260.81% increase. The company also saw a substantial improvement in profitability, with a 44.85% increase in profit. The company's net worth dipped by a decrease of 7.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bellerophon Biotec?
In 2019, Bellerophon Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Chimera Gentec Private LimitedAman Chawla and Pcheena Chawla are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bellerophon Biotec?
Unlock and access historical data on people associated with Bellerophon Biotec, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bellerophon Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bellerophon Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
